Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk?
about
Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosisNew peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.Dapagliflozin in patients with type 2 diabetes mellitus.Increased serum levels of uric acid are associated with sudomotor dysfunction in subjects with type 2 diabetes mellitusSafety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT studyIMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis.Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome.The Potential Biomarkers to Identify the Development of Steatosis in Hyperuricemia.Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE studyHealth benefits of the Mediterranean Diet: an update of research over the last 5 years.Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases.Nutraceuticals in lipid-lowering treatment: a narrative review on the role of chitosan.Type 1 Diabetes and Non-Alcoholic Fatty Liver Disease: When Should We Be Concerned? A Nationwide Study in Brazil.Effects of chitosan on plasma lipids and lipoproteins: a 4-month prospective pilot study.Effects of Losartan vs. Enalapril on the Markers of Metabolic Syndrome.Hyperuricaemia in cardiovascular diseases: a passive or an active player?Early-onset metabolic syndrome in mice lacking the intestinal uric acid transporter SLC2A9.Epicardial fat thickness and nonalcoholic fatty liver disease in obese subjects.Does serum uric acid level affect coronary collaterals in patients with acute coronary syndrome?Vildagliptin: any effect on non-alcoholic fatty liver disease and serum uric acid? Re: Shelbaya S, Rakha S. Effectiveness and safety of vildagliptin and vildagliptin add-on to metformin in real-world settings in Egypt - results from the GUARD study.Obstructive sleep apnea and cardiovascular risk: is metabolic syndrome the link?Serum Uric Acid, Gender, and Low Ankle Brachial Index in Adults With High Cardiovascular Risk.Chicken or Egg Causality Paradox Between Insulin Resistance and Epicardial Fat.
P2860
Q28084150-0EEEF9E8-7966-4A5C-A784-EBE3973541BDQ34398065-A8CC62AB-1CC7-4DAC-9BC9-2CCA9B2D9CF7Q35064363-E132E378-414F-4D5C-9A46-602A79881F3BQ35219367-79C8FC19-00AA-4016-8988-5C750CA7DD41Q35674320-C4761B5D-2C45-4509-B452-E324FA1EDF07Q35691372-873B621B-F602-4F39-8A15-AF1C8CEAF55CQ35819589-4078BBE8-F7E0-4184-9DA1-BFE6033882A9Q35927066-A2472E12-FFB1-44BB-90F9-FC79EDC82E3FQ36984049-9ABA2E5D-D6F2-46E6-8DB0-8DECCA0D457CQ38207982-00BB0889-2FF2-4223-B6B0-02A574DC5F22Q38208727-61793349-69A8-4BAD-8760-0D5549E831A2Q38231113-E8D4B307-DEA8-4EC3-897B-05D3DD4E3A17Q38623900-7C0BEE31-74FE-4237-875A-47DDC11017D8Q39399592-E4A2D57F-6FC8-4972-BA96-DEBC5951835DQ42023930-B494DDF7-EAF9-4AA8-A4C2-0BD288CF7EF2Q42756654-67F50826-F80C-48F6-AE9A-7F0AE3760BD8Q43173125-D607D979-20F7-4658-9E35-39C265B4D93EQ43603019-B1B4FB9C-1E6C-49ED-AAD2-CB6361B91269Q45214467-C992E439-5608-4D1E-9679-D1D2071382EDQ46357255-D08D1A38-3D1A-485E-9215-50BBE4F59F98Q48259221-36F00B5B-CDE1-4548-81C2-87CC5207D850Q51309856-B2F5967D-2937-446C-A3E2-2835606481CEQ53786100-92945FB0-75DF-4A8E-82D7-FE90E36BE78C
P2860
Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk?
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Hyperuricaemia and non-alcohol ...... mplications for vascular risk?
@en
Hyperuricaemia and non-alcoholic fatty liver disease
@nl
type
label
Hyperuricaemia and non-alcohol ...... mplications for vascular risk?
@en
Hyperuricaemia and non-alcoholic fatty liver disease
@nl
prefLabel
Hyperuricaemia and non-alcohol ...... mplications for vascular risk?
@en
Hyperuricaemia and non-alcoholic fatty liver disease
@nl
P1476
Hyperuricaemia and non-alcohol ...... mplications for vascular risk?
@en
P2093
Asterios Karagiannis
Niki Katsiki
P304
P356
10.2174/157016111797484152
P577
2011-11-01T00:00:00Z